An experimental drug for mesothelioma takes a counterintuitive approach: it disables PRX3, an antioxidant defense that tumor cells use to survive intense oxidative stress. Mesothelioma is an aggressive cancer linked to asbestos, and currently has few effective treatment options.
According to the report, the drug kills cancer cells by removing this protective mechanism. Rather than overwhelming tumors with more oxidative damage, it turns their own defense system against them.
Because the drug is still experimental and the information comes from a single ScienceDaily report, there is no independent source to compare the findings with. The central claim is that PRX3 represents a vulnerability that can be exploited therapeutically.